Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | KAT8 | Q9H7Z6 | 10/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.37 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.37 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | EP300 | Q09472 | 10/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL407635 | 1.00 | SIRT5 (0.41) | SIRT5NPSR1KAT8MEN1KMT2A | |
| SCHEMBL19763389 | 0.93 | SIRT5 (0.41) | SIRT5NPSR1KAT8MEN1KMT2A | |
| SCHEMBL403539 | 0.93 | SIRT5 (0.41) | SIRT5NPSR1KAT8MEN1KMT2A | |
| SCHEMBL403538 | 0.93 | SIRT5 (0.41) | SIRT5NPSR1KAT8MEN1KMT2A | |
| SCHEMBL405643 | 0.92 | METTL3 (0.41) | SIRT5NPSR1KAT8MEN1KMT2A | |
| SCHEMBL405642 | 0.92 | METTL3 (0.41) | SIRT5NPSR1KAT8MEN1KMT2A | |
| SCHEMBL4951235 | 0.85 | XDH (0.36) | SIRT5NPSR1MEN1KMT2AMCL1 | |
| SCHEMBL4951228 | 0.85 | XDH (0.36) | SIRT5NPSR1MEN1KMT2AMCL1 | |
| SCHEMBL402928 | 0.84 | SIRT5 (0.39) | SIRT5NPSR1KAT8MEN1KMT2A | |
| SCHEMBL1741894 | 0.84 | SIRT5 (0.39) | SIRT5NPSR1KAT8MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2387998-A1 | Methods for treating degenerative diseases/injuries | Glaxosmithkline LLC (US) | 2011-11-23 | — | — | EP | claimed |
| US-20110254608-A1 | LEVEL CONTROL CIRCUIT, LEVEL CONTROL METHOD, AND LEVEL CONTROL SYSTEM | FUJITSU LIMTED (JP) | 2011-10-20 | — | — | US | claimed |
| US-20080286865-A1 | Methods for the Preservation of Platelet Efficacy During Storage | SMITHKLINE BEECHAM CORPORATION | 2008-11-20 | — | — | US | claimed |
| EP-1622609-A4 | METHODS FOR TREATING DEGENERATIVE DISEASES/INJURIES | SMITHKLINE BEECHAM CORP (US) | 2008-09-03 | — | — | EP | claimed |
| EP-1942906-A2 | METHODS FOR THE PRESERVATION OF PLATELET EFFICACY DURING STORAGE | SmithKline Beecham Corporation (US) | 2008-07-16 | — | — | EP | claimed |
| WO-2008073864-A1 | NOVEL COMBINATIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-19 | — | — | WO | claimed |
| EP-1889838-A1 | Thrombopoietin mimetics | SmithKline Beecham Corporation (US) | 2008-02-20 | — | — | EP | claimed |
| US-7332481-B2 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-19 | — | — | US | claimed |
| US-20070129338-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION | 2007-06-07 | — | — | US | claimed |
| US-20070105824-A1 | Methods for treating degenerative diseases/injuries | GLAXO GROUP LIMITED (GB) | 2007-05-10 | — | — | US | claimed |
| WO-2007044982-A2 | METHODS FOR THE PRESERVATION OF PLATELET EFFICACY DURING STORAGE | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-19 | — | — | WO | claimed |
| JP-2006525352-A | — | — | 2006-11-09 | — | — | JP | claimed |
| EP-1622609-A2 | METHODS FOR TREATING DEGENERATIVE DISEASES/INJURIES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-08 | — | — | EP | claimed |
| WO-2004096154-A2 | METHODS FOR TREATING DEGENERATIVE DISEASES/INJURIES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-11-11 | — | — | WO | claimed |
| US-20040019190-A1 | Thrombopoietin mimetics | NOVARTIS AG (CH) | 2004-01-29 | — | — | US | claimed |
| US-20180000785-A1 | METHODS FOR TREATING DEGENERATIVE DISEASES/INJURIES | NOVARTIS AG (CH) | 2018-01-04 | — | — | US | disclosed |
| US-20160287560-A1 | METHODS FOR TREATING DEGENERATIVE DISEASES/INJURIES | NOVARTIS AG (CH) | 2016-10-06 | — | — | US | disclosed |
| EP-1622609-A2 | METHODS FOR TREATING DEGENERATIVE DISEASES/INJURIES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004096154-A2 | METHODS FOR TREATING DEGENERATIVE DISEASES/INJURIES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040019190-A1 | Thrombopoietin mimetics | NOVARTIS AG (CH) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129338-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | SIRT5 3697/4885NPSR1 508/4885KAT8 4811/4885 |
| US-20160287560-A1 | METHODS FOR TREATING DEGENERATIVE DISEASES/INJURIES | MPL, PLAT, TPO | SIRT5 2639/4885NPSR1 55/4885KAT8 4752/4885 |
| US-20180000785-A1 | METHODS FOR TREATING DEGENERATIVE DISEASES/INJURIES | MPL, PLAT, TPO | SIRT5 2639/4885NPSR1 55/4885KAT8 4752/4885 |
| US-20070105824-A1 | Methods for treating degenerative diseases/injuries | MPL, PLAT, TPO | SIRT5 2639/4885NPSR1 55/4885KAT8 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.